Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
BioPro Medical Ltd Data Analysis - Medistat |
---|---|
Information provided by: | BioPro Medical Ltd |
ClinicalTrials.gov Identifier: | NCT00881140 |
The purpose of this study is to evaluate the effect of daily dosage of vaginally mifepristone on reduction of uterine fibroids size and the symptoms associated with uterine fibroids.
Condition | Intervention | Phase |
---|---|---|
Uterine Fibroid Vaginal Bleeding. |
Drug: mifepristone vaginal tablets |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa) |
Estimated Enrollment: | 30 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
antiprogestin: Experimental
Daily use of 10 mg administrated per vagina
|
Drug: mifepristone vaginal tablets
Daily use of 10 mg administrated per vagina for 3 months
|
Uterine fibroids are benign tumors of the uterus made up of smooth muscle and the extracellular matrix proteins Collagen and Elastin. They are exceptionally common; the cumulative incidence of a diagnosis of fibroids in women aged 25 to 45 is approximately 30 percent.
Uterine fibroids can cause abnormal uterine bleeding, dysmenorrhea, lower back pain and non-cyclic pelvic pain. They also can contribute to symptoms related to an enlarging pelvic mass (e.g., urinary frequency or constipation). Uterine fibroids are also associated with an increased risk of complications of pregnancy, and with infertility, although it is unclear whether this association is causative. Symptoms associated with uterine fibroids can have a significant impact on quality of life, with scores on standard measures that are comparable to those for other major chronic diseases
Ages Eligible for Study: | 30 Years to 53 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: shlomit cohen, mrs | 972-54-3009570 | shlomitc@lapidot.com |
Israel | |
Gynecolaoy department - Shiba Medical Center Tel Hashomer | Recruiting |
Ramat Gan, Israel, 52621 | |
Contact: Aviva Alagem, nurse Aviva.Alagem@sheba.health.gov.il | |
Sub-Investigator: Ronit Machtinger, dr' | |
Sub-Investigator: Yaron Rabinovitz, dr' | |
Principal Investigator: Daniel Seidman, prof' | |
Sub-Investigator: Shlomi Cohen, dr' | |
Sub-Investigator: Dalia Admon, dr' | |
Sub-Investigator: Yinon Gilboa, dr' |
Principal Investigator: | Daniel Seidman, Prof' | unaffiliation |
Responsible Party: | Lapidot group ( Dr. Tamar Lifshitz ) |
Study ID Numbers: | bp001, 5300/08 |
Study First Received: | April 14, 2009 |
Last Updated: | April 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00881140 History of Changes |
Health Authority: | Israel: Ministry of Health |
oral mifepristone vaginal tablets |
Myofibroma Contraceptive Agents Hormone Antagonists Contraceptives, Oral Contraceptive Agents, Female Hormones, Hormone Substitutes, and Hormone Antagonists Mifepristone |
Hemorrhage Contraceptives, Postcoital Leiomyoma Hormones Neoplasms, Connective and Soft Tissue Connective Tissue Diseases |
Neoplasms, Muscle Tissue Contraceptives, Postcoital, Synthetic Contraceptive Agents Hormone Antagonists Contraceptives, Oral Physiological Effects of Drugs Contraceptive Agents, Female Hormones, Hormone Substitutes, and Hormone Antagonists Reproductive Control Agents Leiomyoma Neoplasms, Connective and Soft Tissue Therapeutic Uses Menstruation-Inducing Agents |
Abortifacient Agents Connective Tissue Diseases Contraceptives, Oral, Synthetic Abortifacient Agents, Steroidal Myofibroma Neoplasms by Histologic Type Mifepristone Contraceptives, Postcoital Luteolytic Agents Pharmacologic Actions Neoplasms Neoplasms, Connective Tissue |